The analysis included 234 patients with early symptomatic Alzheimer disease initiating lecanemab. HealthDay News — Treatment of Alzheimer disease with lecanemab is feasible in a specialty memory ...

Analysis included 234 patients with early symptomatic Alzheimer disease initiating lecanemab (Aug. 1, 2023, to Oct. 1, 2024). The researchers found that infusion-related reactions occurred in 37 ...

Patients with early Alzheimer’s disease (AD) who initiated lecanemab treatment at a specialty memory clinic showed an expected and manageable side-effect profile, new research showed.

Proposed intravenous maintenance dosing application to reduce lecanemab infusion frequency from every two weeks to every four weeks for eligible adult UK patients after initial 18 months of treatment ...

Following the news of two lecanemab-related deaths reported on the eve of the Clinical Trials on Alzheimer’s Disease (CTAD) 2022 conference, Eisai has now presented the full results from its ...

In a real-world study of 234 Alzheimer’s patients, Washington University researchers found that lecanemab caused severe side effects in just 1%. Patients with very mild symptoms had the lowest risk ...

Serious side effects of lecanemab can be safely managed, researchers say No patients died of brain swelling and bleeding due to lecanemab Only 4% of patients needed to quit lecanemab due to brain ...

Lecanemab (Leqembi) modestly slows Alzheimer’s by helping the body flush out amyloid beta proteins associated with toxic plaques in the brain. But in clinical trials the drug also came with a ...

No patients died of brain swelling and bleeding due to lecanemab Only 4% of patients needed to quit lecanemab due to brain swelling and bleeding, and only 1% required hospitalization THURSDAY ...

Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer's disease with a claim that their new drug lecanemab showed a "highly statistically ...

Eisai Europe and Biogen Idec have announced the validation of a Marketing Authorisation Variation by the Medicines and Healthcare products Regulatory Agency (MHRA) for lecanemab – marketed as Leqembi® ...

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...